Human Lysozyme Goat Milk for the Prevention of Graft Versus Host Disease in Patients With Blood Cancer Undergoing a Donor Stem Cell Transplant

This study tests whether drinking milk from goats that produce human lysozyme — an antibacterial protein found in human breast milk — can help prevent graft versus host disease (GVHD) in patients undergoing allogeneic stem cell transplantation (receiving a stem cell transplant from a donor). GVHD occurs when the donor's immune cells attack the recipient's body and is a major cause of complications and death after transplant. Human lysozyme has natural antimicrobial properties and may help protect the gut lining, which is often damaged by GVHD. Participants will consume the special milk as a supplement alongside their standard post-transplant care. You may be eligible if: - You are 12 years of age or older - You are undergoing an allogeneic stem cell transplant for a blood cancer from a matched related or unrelated donor (8/8 HLA match) - You are receiving a myeloablative conditioning regimen with total body irradiation - Your heart function (ejection fraction > 50%), lung function (DLCO or FVC > 50%), liver tests, and kidney function meet study criteria - You are willing to use birth control during the study and for 90 days after You may NOT be eligible if: - You are lactose intolerant or have a milk product intolerance - You are pregnant or breastfeeding - You have an active or uncontrolled infection (including active hepatitis B or C, or HIV) - You have had another malignancy within the past 2 years (except non-melanoma skin cancer or cervical carcinoma in situ) - You are enrolled in another investigational drug study Talk to your doctor to see if this trial is right for you.